echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Blood: Prognosis for CLL patients infected with the new coronavirus.

    Blood: Prognosis for CLL patients infected with the new coronavirus.

    • Last Update: 2020-08-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Given age, comorbidities, and immune dysfunction, Patients with CLL may have a particularly high risk of infection and have a poor prognosis associated with coronavirus-19 disease (COVID-19). Reliable analysis of the prognosis of CLL patients
    , especially the examination of baseline characteristics and the effectiveness of CLL treatment, is essential for the proper management of CLL patients in the event of a new coronapneumonia pandemic.
    Mato and others analyzed patients with symptomatic CLL who were diagnosed with COVID-19 infection in 43 international centres (n-198).
    the hospitalization rate of these 198 patients was 90%.
    the median age of confirmed COVID-19 infection was 70.5 years.
    median CIRS score is 8 (range 4-32).
    39% of patients were initially treated (observation and wait) and 61% had received at least one CLL treatment (median of two).
    90 (45%) patients were treated with CLL when they were diagnosed with COVID-19, most lying with BTK inhibitors (BTKi, 76%).
    median follow-up for 16 days with an overall fatality rate (CFR) of 33%. the probability of hospitalization, entering ICU, intubation and death due to COVID-19 hospitalization, intake and death of patients with
    primary and previous treatment was similar, at 89% vs 90%, 35% vs 36%, 33% vs 25% and 37% vs 32%, respectively.
    the treatment of BTKi CLL at the time of COVID-19 does not affect the patient's survival (CFR: 34% vs 35%).
    this study suggests that CLL patients hospitalized with COVID-19 are at high risk of death regardless of the stage of CLL's disease or treatment status.
    future epidemiological studies are needed to assess the risk of SARS-CoV-2 infection, and these data should be independently validated.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.